New drug combo may reboot treatment for advanced liver cancer
NCT ID NCT07184424
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long patients lived without their cancer growing and overall survival. This is a small, early study, so results are not yet proven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide
What this could lead to
If it works, this could give doctors a new way to control advanced liver cancer when standard treatments stop working.
What could go wrong
This is a very small, early study with only 24 patients and no comparison group. The results may not apply to everyone, and adding a drug can increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China